Evidence map›Paper›PMID 29397516›Full record

ArticleMolecular biology reports2018

Role of polymorphic XRCC6 (Ku70)/XRCC7 (DNA-PKcs) genes towards susceptibility and prognosis of lung cancer patients undergoing platinum based doublet chemotherapy.

Amrita Singh, Navneet Singh, Digambar Behera, Siddharth Sharma

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. DNA Damage and Its Role in Cancer Therapeutics.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Amrita SinghDepartment of Biotechnology, Thapar University, Patiala, Punjab, 147002, India.
Navneet SinghDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Sector 14, Chandigarh, India.
Digambar BeheraDepartment of Pulmonary Medicine, Post Graduate Institute of Medical Education and Research (PGIMER), Sector 14, Chandigarh, India.
Siddharth SharmaDepartment of Biotechnology, Thapar University, Patiala, Punjab, 147002, India. siddharthsharma.phd@thapar.edu.ORCID http://orcid.org/0000-0001-9414-3771
Post Graduate Institute of Medical Education and Research · INThapar Institute of Engineering & Technology · IN

Funding

Indian Council of Medical Research 5/13/126/2011/NCD-III
6 · The paper itself

Abstract

The DNA repair genes XRCC6 and XRCC7 formed an integral part of double strand break repair (DSBR) pathway. The two genes are thought to play an important role in the repair of lethal double strand damage on DNA. Polymorphic DSBR genes are studied to effect genomic stability. We intend to explore the association of DSBR genes i.e. XRCC6 and XRCC7 with susceptibility and survival in North Indian lung cancer patients. DNA isolation and genotyping was done for 320 controls and 330 lung cancer cases enrolled in the study. Each and every lung cancer study subjects were made a telephonic call and were followed for their health after administration of chemotherapy. Statistical analysis for susceptibility was done using logistic regression analysis. Survival analysis was done using Kaplan-Meier followed by Cox-regression. Small cell lung cancer (SCLC) subtype posed an amplified risk towards lung cancer in case of XRCC7 6721G>T (OR = 4.11, p = 0.0040). Gene-environment interaction analysis revealed that non-smokers with heterozygous genotype (CG) in case of XRCC6 61C>G showed a strong protective effect (OR = 0.38, p = 0.01) towards lung cancer. Survival analysis revealed poor prognosis in case of XRCC6 61C>G SCLC subtype. XRCC6 and XRCC7 were not involved in overall susceptibility and survival. However, in case of XRCC7 6721G>T subjects with SCLC subtype showed an increased susceptibility while poor prognosis in case of XRCC6 61C>G.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarboplatinCase-Control StudiesCisplatinDNA-Activated Protein KinaseDNA Breaks, Double-StrandedDNA, NeoplasmDocetaxelFemaleGenetic Predisposition to DiseaseHumansKaplan-Meier EstimateKu AutoantigenLung NeoplasmsMaleMiddle AgedCarboplatinCisplatinDNA-Activated Protein KinaseDNA, NeoplasmDocetaxelKu AutoantigenNuclear ProteinsPemetrexedPRKDC protein, humanTaxoidsXrcc6 protein, humanADCCGenotypeLung cancerSCLCSQCCSurvivalSusceptibility

Identifiers

PMID29397516
OpenAlexW2786015925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.